Table 3 Cox regression analysis of OS in ICC patients in the training group

Age, < 60/ ≥ 60

1.194

0.861–1.655

0.287

Gender, male/female

0.852

0.614–1.182

0.338

History of hepatitis B infection, -/ + 

0.657

0.463–0.932

0.019

0.873

0.593–1.286

0.492

Hepatolithiasis, -/ + 

1.697

1.110–2.596

0.015

1.261

0.780–2.037

0.344

ALT (U/L), < 50/ ≥ 50

1.412

0.981–2.034

0.064

AST (U/L), < 40/ ≥ 40

1.748

1.242–2.461

0.001

0.889

0.562–1.405

0.613

Bilirubin (umol/L), < 21/ ≥ 21

1.782

1.190–2.667

0.005

1.615

0.971–2.689

0.065

AFP (ng/ml), < 7/ ≥ 7

0.849

0.603–1.196

0.349

CEA (ng/ml), < 5/ ≥ 5

2.115

1.511–2.961

 < 0.001

1.463

0.990–2.161

0.056

CA19-9 (U/ml), < 37/ ≥ 37

2.902

1.976–4.260

 < 0.001

1.693

1.090–2.630

0.019

Tumor differentiation, well-moderate/poor

3.569

2.476–5.147

 < 0.001

2.422

1.611–3.642

 < 0.001

Tumor number, 1/ ≥ 2

1.809

1.273–2.571

0.001

Tumor size (cm), < 5/ ≥ 5

1.735

1.201–2.508

0.003

TBS ≥ 6.3

2.169

1.558–3.019

 < 0.001

PT (s)

1.131

1.006–1.271

0.052

INR

0.980

0.890–1.079

0.685

APTT (s)

0.997

0.969–1.025

0.819

White blood cell count (10^9/L)

1.017

0.960–1.078

0.561

Neutrophil count (10^9/L)

1.033

0.971–1.100

0.305

HALP < 37.1

2.287

1.642–3.185

 < 0.001

Vascular invasion, -/ + 

4.205

2.972–5.949

 < 0.001

2.152

1.388–3.335

0.001

Perineural invasion, -/ + 

2.212

1.586–3.086

 < 0.001

1.433

0.984–2.087

0.061

Lymph node invasion, -/ + 

2.297

1.564–3.374

 < 0.001

1.331

0.863–2.053

0.196

HTS grade

 1

 2

2.480

1.615–3.807

 < 0.001

1.626

1.023–2.583

0.040

 3

4.639

3.026–7.111

 < 0.001

2.462

1.503–4.032

 < 0.001